Genetic Variability in Clopidogrel Metabolism Exposes Inequities in Coronary Artery Disease Treatment
Original framing: “[Correspondence] Clopidogrel versus aspirin for coronary artery disease” — The Lancet
The original framing omits the historical context of pharmacogenomics and its potential to exacerbate existing health disparities. It also neglects the perspectives of patients from marginalized communities who may face barriers to accessing genetic testing and targeted treatments. Furthermore, the narrative fails to address the structural causes of healthcare inequity, such as unequal access to healthcare services and lack of diversity in clinical trials.
Low structural omission detected in mainstream coverage.
This narrative was produced by Marco Valgimigli and colleagues, a group of researchers with expertise in cardiology and pharmacogenomics, for the medical community and patients with coronary artery disease. The framing serves to highlight the importance of genetic testing in optimizing treatment outcomes, while obscuring the broader structural issues of healthcare inequity and access.
The development of pharmacogenomics has a complex history, with early pioneers like Garrod and Garrod's work on alkaptonuria highlighting the importance of genetic variation in disease susceptibility. However, the field has also been shaped by colonialism and the exploitation of Indigenous knowledge, leading to ongoing inequities in healthcare access and outcomes.
The efficacy of clopidogrel in preventing coronary artery disease is compromised by genetic variability in CYP2C19 metabolism, disproportionately affecting patients of certain ethnicities.